Literature DB >> 27183340

Screening of the COL2A1 mutation in idiopathic osteonecrosis of the femoral head.

Yuma Sakamoto1,2, Takuaki Yamamoto3, Noriko Miyake4, Naomichi Matsumoto4, Aritoshi Iida2, Yasuharu Nakashima1, Yukihide Iwamoto5, Shiro Ikegawa2.   

Abstract

Idiopathic osteonecrosis of the femoral head (idiopathic ONFH) is an ischemic disorder resulting in necrosis of the subchondral bone of the femoral head. COL2A1 mutations, including c.3508G>A, have been reported to be involved in its etiology. However, the etiological role of COL2A1 mutations in idiopathic ONFH remains controversial, because the pathology of idiopathic ONFH is ischemic necrosis, not epiphyseal dysplasia usually seen in the diseases caused by COL2A1 mutations. The purpose of this study is to examine whether COL2A1 mutations have causal relation with idiopathic ONFH or not. We recruited 1,451 Japanese patients with idiopathic ONFH, including steroid-, alcohol-, and neither steroid nor alcohol-associated (neither-associated) ONFH. The diagnosis was based on the criteria of the Japanese Research Committee on idiopathic ONFH of the Ministry of Health, Labour and Welfare. By whole-exome sequencing, entire COL2A1 coding regions and flanking introns were analyzed in 49 neither-associated ONFH patients. In addition, the c.3508G>A mutation of COL2A1 was checked in all idiopathic ONFH patients using the invader assay. Whole-exome sequencing did not detect any COL2A1 mutations in the 49 patients. The c.3508G>A mutation was not found in any of the 1,451 patients. In conclusion, COL2A1 is unlikely to cause idiopathic ONFH. Epiphyseal dysplasia of the femoral head caused by COL2A1 mutations may radiographically mimic idiopathic ONFH. COL2A1 mutations should prompt clinical re-evaluation of the patient's phenotype.
© 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:768-774, 2017. © 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  COL2A1; dysplasia; mutation; osteonecrosis

Mesh:

Substances:

Year:  2016        PMID: 27183340     DOI: 10.1002/jor.23300

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  6 in total

1.  Collagen type V a2 (COL5A2) is decreased in steroid-induced necrosis of the femoral head.

Authors:  Fan Yang; Pengbo Luo; Hao Ding; Changqing Zhang; Zhenhong Zhu
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  Association of Genes Variants in RANKL/RANK/OPG Signaling Pathway with the Development of Osteonecrosis of the Femoral Head in Chinese Population.

Authors:  Yang Song; Zhen-Wu Du; Qi-Wei Yang; Ming Ren; Qing-Yu Wang; Ao Wang; Gao-Yang Chen; Hai-Yue Zhao; Tao Yu; Gui-Zhen Zhang
Journal:  Int J Med Sci       Date:  2017-06-23       Impact factor: 3.738

3.  Gene testing for osteonecrosis of the femoral head in systemic lupus erythematosus using targeted next-generation sequencing: A pilot study.

Authors:  Hong-Sheng Sun; Qing-Rui Yang; Yan-Yan Bai; Nai-Wen Hu; Dong-Xia Liu; Cheng-Yong Qin
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

4.  Urinary miRNAs as biomarkers for idiopathic osteonecrosis of femoral head: A multicentre study.

Authors:  Yongheng Ye; Yue Peng; Peiheng He; Qinqin Zhang; Dongliang Xu
Journal:  J Orthop Translat       Date:  2020-02-21       Impact factor: 5.191

5.  Association of MTHFR rs1801133 and homocysteine with Legg-Calvé-Perthes disease in Mexican patients.

Authors:  José Guillermo Buendía-Pazarán; Edgar Hernández-Zamora; Armando O Rodríguez-Olivas; Leonora Casas-Ávila; Margarita Valdés-Flores; Elba Reyes-Maldonado
Journal:  Orphanet J Rare Dis       Date:  2022-03-09       Impact factor: 4.123

6.  COL2A1 mutation (c.3508G>A) leads to avascular necrosis of the femoral head in a Chinese family: A case report.

Authors:  Fang Liu; Zhizheng Xiong; Qi Liu; Jinxi Hu; Wenhua Li; Na Zhang
Journal:  Mol Med Rep       Date:  2018-05-07       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.